Form 4: Pyxis Oncology Director John Flavin Reports Acquisition and Disposal of Common Stock

Director John Flavin of Pyxis Oncology, Inc. reports acquiring and disposing of common stock on March 26, 2024.

Summary

• On March 26, 2024, John L. Flavin, a director of Pyxis Oncology, Inc., acquired 35,219 shares of common stock.
• The acquisition was made at a price of $0 per share.
• On the same day, Flavin disposed of an unspecified amount of common stock.
• Following these transactions, Flavin beneficially owns 413,015 shares of Pyxis Oncology, Inc.
• The reported transaction included restricted stock units that vest 100% on the first anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the actions of company leadership but doesn't necessarily indicate broader industry trends.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it reflects insider activity, but the overall impact is likely minimal given the size of the transaction relative to the company's total outstanding shares.

Key Dates